Codiak BioSciences, Inc. (CDAK) Financial Statements (2024 and earlier)

Company Profile

Business Address 35 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2022
MRQ
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including: 76,90088,915
Cash and cash equivalents 76,93888,915
Other undisclosed cash, cash equivalents, and short-term investments (38) 
Prepaid expense 2,5932,598
Deferred costs 200200
Other undisclosed current assets 10,4782,045
Total current assets: 90,17193,758
Noncurrent Assets
Operating lease, right-of-use asset 21,95722,003
Property, plant and equipment 23,47931,410
Restricted cash and investments 4,1704,170
Other undisclosed noncurrent assets 31,893 
Total noncurrent assets: 81,49957,583
TOTAL ASSETS: 171,670151,341
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 11,54110,888
Accounts payable 1,8382,018
Accrued liabilities 9,7038,870
Deferred revenue 12,9635,281
Other undisclosed current liabilities 2,6611,482
Total current liabilities: 27,16517,651
Noncurrent Liabilities
Long-term debt and lease obligation 60,31461,500
Long-term debt, excluding current maturities 25,43024,960
Liabilities, other than long-term debt 30,68657,416
Deferred revenue 30,68657,416
Operating lease, liability 34,88436,540
Other undisclosed noncurrent liabilities  207
Total noncurrent liabilities: 91,000119,123
Total liabilities: 118,165136,774
Equity
Equity, attributable to parent 53,50514,567
Common stock 22
Additional paid in capital 378,750302,655
Accumulated deficit (325,247)(288,090)
Total equity: 53,50514,567
TOTAL LIABILITIES AND EQUITY: 171,670151,341

Income Statement (P&L) ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
Revenues 22,9352,915
Sublease income 1,850861
Gross profit: 22,9352,915
Operating expenses (92,484)(93,833)
Operating loss: (69,549)(90,918)
Nonoperating income (expense) 32,392(747)
Investment income, nonoperating 33,308253
Other nonoperating income 1,780906
Interest and debt expense (2,696)(1,906)
Loss from continuing operations: (39,853)(93,571)
Loss before gain (loss) on sale of properties:(39,853)(93,571)
Other undisclosed net income 2,6961,906
Net loss attributable to parent: (37,157)(91,665)
Preferred stock dividends and other adjustments  (10,831)
Net loss available to common stockholders, diluted: (37,157)(102,496)

Comprehensive Income ($ in thousands)

9/30/2022
TTM
12/31/2021
12/31/2020
Net loss: (37,157)(91,665)
Comprehensive loss: (37,157)(91,665)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (43)
Comprehensive loss, net of tax, attributable to parent: (37,157)(91,708)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: